Technical Analysis for 0Y3M - Prothena Corp. PLC
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Slingshot Bearish | Bearish Swing Setup | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | 3.89% | |
New Downtrend | Bearish | 3.89% | |
Gilligan's Island Buy Setup | Bullish Swing Setup | 3.89% | |
New 52 Week Low | Weakness | 3.89% | |
Multiple of Ten Bullish | Other | 3.89% |
Alert | Time |
---|---|
Gilligan's Island Bullish Entry | about 22 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Up 3% | about 22 hours ago |
Up 2% | about 22 hours ago |
Up 1% | about 22 hours ago |
Get this analysis on your stocks daily!
Prothena Corp. PLC Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Classification
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 76.37 |
52 Week Low | 19.82 |
Average Volume | 2,265 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 25.52 |
20-Day Moving Average | 22.43 |
10-Day Moving Average | 21.09 |
Average True Range | 0.91 |
RSI (14) | 37.11 |
ADX | 25.89 |
+DI | 23.79 |
-DI | 41.60 |
Chandelier Exit (Long, 3 ATRs) | 23.43 |
Chandelier Exit (Short, 3 ATRs) | 22.55 |
Upper Bollinger Bands | 25.46 |
Lower Bollinger Band | 19.41 |
Percent B (%b) | 0.28 |
BandWidth | 26.99 |
MACD Line | -1.51 |
MACD Signal Line | -1.55 |
MACD Histogram | 0.0368 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 21.08 | ||||
Resistance 3 (R3) | 21.08 | 21.08 | 21.08 | ||
Resistance 2 (R2) | 21.08 | 21.08 | 21.08 | 21.08 | |
Resistance 1 (R1) | 21.08 | 21.08 | 21.08 | 21.08 | 21.08 |
Pivot Point | 21.08 | 21.08 | 21.08 | 21.08 | 21.08 |
Support 1 (S1) | 21.08 | 21.08 | 21.08 | 21.08 | 21.08 |
Support 2 (S2) | 21.08 | 21.08 | 21.08 | 21.08 | |
Support 3 (S3) | 21.08 | 21.08 | 21.08 | ||
Support 4 (S4) | 21.08 |